|1.||Weiser, Thomas: 4 articles (01/2008 - 09/2002)|
|2.||Bai, Chunxue: 3 articles (04/2012 - 01/2004)|
|3.||Peil, Hubertus: 3 articles (01/2008 - 01/2002)|
|4.||de Mey, Christian: 3 articles (01/2008 - 01/2002)|
|5.||Drewa, Tomasz: 3 articles (11/2007 - 09/2005)|
|6.||Wolski, Zbigniew: 3 articles (11/2007 - 09/2005)|
|7.||de Mey, C: 2 articles (12/2015 - 08/2000)|
|8.||Roomans, Godfried M: 2 articles (06/2015 - 11/2013)|
|9.||Varelogianni, Georgia: 2 articles (06/2015 - 11/2013)|
|10.||Higaki, Katsumi: 2 articles (01/2015 - 04/2013)|
01/01/1986 - "However, remission of the cough, of the chest pathological signs, as well as the improvement of the lung radiographical pictures were significantly more rapid in children treated with ambroxol than in those who received the antibiotic alone. "
09/01/2006 - "This study was designed to evaluate the "real life" behavior of consumers with non-prescription access to an ambroxol cough syrup with special focus on tolerability and the pattern of product usage. "
02/01/1998 - "The study suggests, that ambroxol has a cough-suppressive effect. "
02/01/1998 - "In the present study, the effects of ambroxol on the cough reflex in the cats were investigated. "
01/01/1987 - "The first trial involving 60 patients daily treated with 120 mg of ambroxol showed significant differences (p less than 0.05) in sputum volume, sputum viscosity, difficulty of expectoration, and severity of cough when compared with the placebo group. "
12/01/2010 - "The current data suggest that ambroxol could be effective for clinical neuropathic SCI pain. "
12/01/2005 - "Ambroxol (1g/kg) was only weakly effective in models for acute pain, but effectively reduced pain symptoms in all other models; in some cases it completely reversed pain behaviour. "
01/01/2014 - "A meta-analysis of the 5 controlled trials resulted in a difference in pain reduction compared to placebo of -0.11 (95% CI [-0.15, -0.07]; p < 0.0001) favouring ambroxol 20 mg. Quality of reporting of the studies was low. "
01/01/2002 - "All treatments led to a reduction of pain intensity; the means (+/- SD) SPIDnorm after the 1st lozenge were 0.53 +/- 0.28 or 0.50 +/- 0.30 or 0.38 +/- 0.28 with 20 mg or 30 mg ambroxol hydrochloride or placebo respectively in study I, and 0.53 +/- 0.30 or 0.60 +/- 0.28 or 0.39 +/- 0.31 in study II; the effect of treatment was statistically significant (p: 0.0002 or p: 0.0033 in study I and p: 0.0005 or p: 0.0001 in study II, respectively, for the comparison of 20 mg or 30 mg ambroxol hydrochloride vs. placebo). "
12/01/2015 - "Pain reduction following ambroxol cream was 2-8 points (NRS) within 15-30 min and lasted 3-8 h. "
01/01/1985 - "Ambroxol has previously been shown to change the airway secretions of patients affected by chronic bronchitis; these secretions significantly improved mucociliary transport when applied to the frog palate. "
01/01/1996 - "This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients. "
10/01/1995 - "To verify the possibility of producing anti-inflammatory effects in a clinically relevant condition, 20 patients with chronic bronchitis, randomly divided into two balanced matched groups, were submitted to a 14 day trial with Ambroxol, 150 mg.day-1, or placebo, according to a double-blind design. "
10/01/1987 - "A controlled trial of ambroxol in chronic bronchitis."
03/01/1987 - "Fourteen subjects with simple chronic bronchitis, who belonged to a "responder" group in an earlier study on the subjective effects of ambroxol, were examined using a double-blind cross-over design comparing 120 mg ambroxol daily and placebo. "
|4.||Pharyngitis (Sore Throat)
01/01/2014 - "Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis."
01/01/2014 - "Selection criteria consisted of randomized controlled trials which compared ambroxol to placebo or any other treatment for sore throat. "
01/01/2008 - "Presently, the evidence from randomised, placebo-controlled, double-blind clinical trials (RCT) with the local anaesthetic ambroxol (CAS 23828-92-4) in the treatment of sore throat is being reviewed. "
12/01/2015 - "Efficacy and Safety of an Oral Ambroxol Spray in the Treatment of Acute Uncomplicated Sore Throat."
01/01/2008 - "It is concluded that lozenges containing 20 mg ambroxol are a safe and efficacious treatment for acute uncomplicated sore throat of recent onset in adult patients."
|5.||Newborn Respiratory Distress Syndrome
05/01/1997 - "This study does not suggest the efficacy of antenatal ambroxol treatment both for the prevention of neonatal respiratory distress syndrome and for the reduction of its severity."
09/01/2009 - "[Efficacy of different dosages of ambroxol hydrochloride in the prevention of neonatal respiratory distress syndrome]."
01/01/2014 - "Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome."
01/01/2011 - "The aim of this study is to assess the effect of Ambroxol, given prenatally on the rate and severity of neonatal respiratory distress syndrome (NRDS) in preterm infants and its potential to replace the corticosteroid prophylaxis in cases where steroids are contraindicated or undesirable. "
02/01/1986 - "The results of this study indicate that Ambroxol compared to Betamethasone can be considered as an effective drug for prevention of neonatal respiratory distress syndrome."
|4.||Methacholine Chloride (Methacholine)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Transforming Growth Factor beta1 (TGF beta 1)
|1.||Dry Powder Inhalers
|2.||Enzyme Replacement Therapy
|3.||Mechanical Ventilators (Ventilator)